RT Journal
A1 Bajaj RR, Wald R, Hackam DG, et al
T1 Use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and cardiovascular outcomes in chronic dialysis patients: A population-based cohort study
JF Archives of Internal Medicine
JO Archives of Internal Medicine
YR 2012
FD April 9
VO 172
IS 7
SP 594
OP 595
DO 10.1001/archinternmed.2012.139
UL http://dx.doi.org/10.1001/archinternmed.2012.139
AB 
Routine use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) for the treatment of cardiovascular disease is well established.1- 2 However, because most randomized controlled trials have excluded patients with advanced chronic kidney disease,3 the role of ACEIs/ARBs in chronic dialysis patients remains poorly defined. Our objective was to determine whether ACEI/ARB use is associated with a reduction in mortality and major adverse cardiovascular events in older chronic dialysis patients.